BILLERICA, Mass.–(BUSINESS WIRE)–Access Vascular, Inc. (AVI), a leader in advanced vascular access technology, today announced the presentation of new, expanded real-world data at the 2025 Infusion Nurses Society (INS) Annual Meeting in Las Vegas. The data reinforces significant improvements in midline catheter outcomes associated with AVI’s proprietary hydrophilic biomaterial (HBM), building on findings previously shared at the Association for Vascular Access Annual Meeting in 2024.
The study was independently designed and conducted by an acute care hospital in Montana and evaluated outcomes across 288 patients. It compared a conventional chlorhexidine gluconate (CHG)-coated polyurethane catheter to Access Vascular’s HydroMID® HBM-based catheter.
Key findings announced at INS 2025:
- 75% Lower Complication Rate: HydroMID® exhibited a 5.3% complication rate, compared with 21.8% for CHG polyurethane.
- Greater Therapy Completion: 95% of HydroMID® patients completed therapy with the original line in place, compared to just 80% for CHG polyurethane.
- Extended Dwell Time: HydroMID® remained in place nearly 40% longer than CHG polyurethane catheters.
“With more than 125 catheters in each study arm, these findings add to the growing body of evidence that our hydrophilic biomaterial platform delivers tangible benefits where it matters most: improved outcomes for patients,” said Jim Biggins, CEO of Access Vascular. “Fewer complications, longer dwell times, and higher rates of therapy completion all support a safer, more efficient experience for patients and providers alike.”
Unlike traditional polyurethane catheters, AVI’s devices are constructed from MIMIX®, a proprietary hydrogel-based material designed to reduce thrombus formation and bacterial adhesion. This fundamental material change targets the root causes of vascular access device failure.
“Concerns relating to frequent complications with our previous midline device kept growing. We felt defeated in our efforts to get our patients to the end of their therapy – we knew we could do better for them,” said Kelsey Pearson, RN, VA-BC at Benefis Hospital. “We have noticed a significant improvement in our outcomes and provided a better patient experience since switching to the HydroMID® catheter.”
About Access Vascular
Access Vascular, Inc. (AVI) is redefining vascular access by engineering devices from a fundamentally better material. The MIMIX® hydrogel platform is designed to reduce the complications associated with traditional catheters, helping clinicians keep lines in place, improving the patient experience and delivering value to hospitals. For more information, please visit www.accessvascularinc.com, and follow us on LinkedIn.
Contacts
Media Contact:
Brad Perriello
Circle Hill Communications
[email protected]
617.817.1385
